- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-702X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Disease-modifying effects of ranibizumab for central retinal vein occlusion ; day:6 ; month:10 ; year:2021 ; pages:1-7
Graefe's archive for clinical and experimental ophthalmology ; (6.10.2021), 1-7
- Creator
-
Huang, Jason M.
Khurana, Rahul N.
Ghanekar, Avanti
Wang, Pin-wen
Day, Bann-Mo
Blodi, Barbara A.
Domalpally, Amitha
Quezada-Ruiz, Carlos
Ip, Michael S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00417-021-05224-x
- URN
-
urn:nbn:de:101:1-2021122318102640573187
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Huang, Jason M.
- Khurana, Rahul N.
- Ghanekar, Avanti
- Wang, Pin-wen
- Day, Bann-Mo
- Blodi, Barbara A.
- Domalpally, Amitha
- Quezada-Ruiz, Carlos
- Ip, Michael S.
- SpringerLink (Online service)
Other Objects (12)
Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
Current Disease-Modifying Therapies in Multiple Sclerosis
Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion
Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global, LUMINOUS study
Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
Disease-modifying treatments in Alzheimer’s disease
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab
Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion
Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
Current Disease-Modifying Therapies in Multiple Sclerosis
Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion
Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global, LUMINOUS study
Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
Disease-modifying treatments in Alzheimer’s disease
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab
Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion
Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
Current Disease-Modifying Therapies in Multiple Sclerosis
Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion
Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global, LUMINOUS study
Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
Disease-modifying treatments in Alzheimer’s disease
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab
Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy